ACAT2 as a novel therapeutic target to treat fatty liver disease
Author:
Open Access
- 10 February 2022
- journal article
- editorial
- Published by Wiley in Journal of Internal Medicine
- Vol. 292 (2) , 175-176
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver DiseaseGastroenterology, 2021
- MAFLD vs NAFLD: Let the contest begin!Liver International, 2020
- LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnoverGut, 2020
- Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver DiseaseCell Metabolism, 2020
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030Journal of Hepatology, 2018
- The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European DescentGastroenterology, 2016
- Sterol O‐Acyltransferase 2‐Driven Cholesterol Esterification Opposes Liver X Receptor‐Stimulated Fecal Neutral Sterol LossLipids, 2016
- Acute Sterol O-Acyltransferase 2 (SOAT2) Knockdown Rapidly Mobilizes Hepatic Cholesterol for Fecal ExcretionPLOS ONE, 2014
- The Enzymes of Neutral Lipid SynthesisJournal of Biological Chemistry, 2001
- Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient miceNature Medicine, 2000